The emergence of Retatrutide ZPHC, at a strength of 120mg, is generating considerable interest within the healthcare community. This novel dual GIP and GLP-1 agonist medication seems to provide significant improvements in weight shedding compared to previous therapies. Initial clinical studies have shown significant declines in weight , conceivably